The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N03 | Antiepileptics | |
3
|
N03A | Antiepileptics | |
4
|
N03AG | Fatty acid derivatives | |
5
|
N03AG04 | Vigabatrin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 2 g |
| Active Ingredient |
|---|
|
Vigabatrin is a selective irreversible inhibitor of GABA transaminase, the enzyme responsible for the breakdown of GABA (gamma aminobutyric acid). Vigabatrin increases the concentration of GABA, the major inhibitory neurotransmitter in the brain. |
| Document | Type | Information Source | |
|---|---|---|---|
| KIGABEQ Soluble tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| SABRIL Film-coated tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| VIGAFYDE Oral solution | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.